Effects of Rosuvastatin and Fluvastatin on Patients With Acute Coronary Syndrome Combining Impaired Glucose Tolerance
10.3969/j.issn.1000-3614.2014.07.007
- VernacularTitle:瑞舒伐他汀和氟伐他汀治疗急性冠状动脉综合征合并糖耐量减低患者的疗效观察
- Author:
Haibing JIANG
;
Lan LI
;
Xiufang LI
;
Jun MA
;
Lati MAO
;
Fengyan XU
;
Zhenrong GE
;
Shubin JIANG
- Publication Type:Journal Article
- Keywords:
Rosuvastatin;
Fluvastatin;
Acute coronary syndrome;
Impaired glucose tolerance
- From:
Chinese Circulation Journal
2014;(7):505-508
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effects of rosuvastatin and lfuvastatin on patients with acute coronary syndrome (ACS) combing impaired glucose tolerance (IGT).
Methods: A total of 215 consecutive ACS patients combing IGT treated in our hospital from 2009-05 to 2011-05 were studied. The patients were randomly divided into 2 groups, Rosuvastatin group, the patients received rosuvastatin10mg/day, n=108 and Fluvastatin group, the patients received fluvastatin 40mg/day, n=107. The total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) levels before and at 6, 12, 24 months after medication, fasting blood glucose (FBG), 2-hour postprandial glucose (2hPBG) and the number of new-onset of diabetes patients were compared between 2 groups.
Results: After treatment, the TC, LDL-C levels were decreased (6, 12, 24 months) and the HDL-C level (12, 24 months), 2hPBG (24 months) were increased in both groups. Compared with Fluvastatin group, Rosuvastatin group had decreased TC and LDL-C (6, 12, 24 months), and increased LDL-C (24 months). With 6, 12, 24 months treatment, the blood lipids reached the standard were more in Rosuvastatin group than those in Fluvastatin group as 35.3%vs 26.1%, 36.4% vs 22.0%, 43.1% vs 31.8% respectively, all P<0.05. With 12 and 24 months treatment, the new-onset diabetes patients in Rosuvastatin group were 11 and 18, in Fluvastatin group were 12 and 17. With 12, 24 months treatment, FBG, 2hPBG levels and the number of new-onset diabetes patients were similar between 2 groups, P>0.05.
Conclusion: Compared with lfuvastatin, the conventional dose of rosuvastatin could better reduce the blood lipids level in ACS patients combing IGT, the effects for preventing ACS patients from IGT to diabetes were similar for both drugs.
